Why Pyxis Oncology, Inc.’s (PYXS) Stock Is Up 5.68%
As of Tuesday, October 20, Pyxis Oncology, Inc.’s PYXS share price has surged by 5.68%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Pyxis Oncology, Inc.’s (PYXS) Stock Is Down 5.83%
As of Friday, October 16, Pyxis Oncology, Inc.’s PYXS share price has dipped by 5.83%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Pyxis Oncology, Inc.’s (PYXS) Stock Is Down 5.22%
As of Tuesday, October 13, Pyxis Oncology, Inc.’s PYXS share price has dipped by 5.22%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Pyxis Oncology, Inc.’s (PYXS) Stock Is Down 5.72%
As of Tuesday, October 06, Pyxis Oncology, Inc.’s PYXS share price has dipped by 5.72%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Pyxis Oncology, Inc.’s (PYXS) Stock Is Down 23.45%
As of Wednesday, September 30, Pyxis Oncology, Inc.’s PYXS share price has dipped by 23.45%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | PYXS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $235.3 | $232.8 | 30% |
|
| Shares Out (Mil) | 64.0 | 53.4 | 53% |
|
| Institutional Ownership | 80.3% | 92.9% | 49% |
|
| Float (Mil) | 78.3 | 41.2 | 56% |
|
| Beta | 1.34 | 0.96 | 77% |
|
| Avg Daily Volume (000s) | 782 | 490 | 66% |
|
| Price Change (52-week) |
(41.9%) | 48.2% | 24% |
|
| Growth | PYXS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (44.1%) | (10.1%) | 8% |
|
| EPS (5yr) | 36.5% | 15.8% | 86 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 63.8% | (15.7%) | 96% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | ($0.278) | ($1.213) | ($1.108) | |
| Month Ago EPS | ($0.278) | ($1.220) | ($1.128) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.275) | ($1.224) | ($1.205) | |
| Year/Year Chg | (29.8%) | (5.3%) | (17.4%) | |
| Financials | PYXS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $11 | $37 | 9% |
|
| Net Income (TTM) (Mil) | ($89) | ($44) | 12% |
|
| EPS (TTM) | ($1.403) | ($1.600) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($68) | ($33) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $8 | $2 | 55% |
|
| Long-Term Debt (Q1) (Mil) | $16 | $4 | 31% |
|
| Enterprise Value (Q1) (Mil) | $251 | $174 | 28% |
|
| Valuation | PYXS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 10.94 | 2.22 | 92% |
|
| P/E | na | 20.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PYXS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 78.4% | 66.9% | 88% |
|
| Net Margin | (803.8%) | (75.3%) | 0% |
|
| ROA | (99.6%) | (47.3%) | 5% |
|
| ROE | (179.1%) | (53.3%) | 5% |
|
| Liabilities to Assets | 79.2% | 29.4% | 74% |
|
| F-Score | 1 | 2 | 1% |
|
Pyxis Oncology, Inc. did not pass any screens on 10/28/2026.
